Cell cycle progression and cell proliferation are tightly controlled processes that are critical for normal development and organogenesis, and deregulation of these processes may result in cancer. The cholesterol synthesis pathway is known to affect cell proliferation and cell cycle progression.[@R1]^,^[@R2] Cholesterol is an essential component of cell membranes and organelles, and its synthesis is thereby tightly regulated by the sterol regulatory element-binding protein (SREBP) family transcription factors.[@R3] Three SREBP family members are known in humans, and they coordinate the expression of fatty acid metabolism and cholesterol metabolism-related genes.[@R3] Additionally, SREBPs have been implicated in cell cycle regulation and have gained attention as the link between lipid synthesis, proliferation, and cell growth.[@R4] Whether the contribution of cholesterol in cell cycle progression is of a regulatory nature or a side-effect of its structural requirement is not known.

Recent studies have uncovered a partner for SREBPs in regulating lipid metabolism -- the miR-33 family microRNAs (miRNAs).[@R5]^--^[@R8] MiRNAs comprise a class of small non-coding RNAs that regulate genes post-transcriptionally by base pairing with sequences in the 3\' untranslated regions (3\' UTRs) of target genes. Because a single miRNA species can target the expression of multiple genes, miRNAs are thought to act as master coordinators of cellular processes. The *mir-33* genes are found in the intronic regions of *Srebp* genes and are co-transcribed with their host genes. Research by multiple groups has shown that miR-33 family miRNAs regulate cholesterol and fatty acid metabolism in mammalian systems, corresponding with the function of their host genes.[@R5]^--^[@R8] Adding to the repertoire of miR-33--SREBP co-regulated processes, in a recent issue of *Cell Cycle*, Cirera-Salinas and colleagues report a role for miR-33 in regulating cell proliferation and cell cycle progression.[@R9]

In Cirera-Salinas et al., researchers first found that miR-33's potential targets include genes involved in cell proliferation and cell cycle such as cyclin-dependent kinase 6 (*Cdk6*) and cyclin D1 (*Ccnd1*), and they further investigated these putative regulatory interactions. They found that transfection of miR-33 in human cell culture significantly inhibited both mRNA and protein levels of these cell cycle genes in addition to that of *Abca1*, a previously identified miR-33 target.[@R5]^--^[@R8] The opposite result was obtained when miR-33 was inhibited using anti-miR-33 oligonucleotides. Luciferase reporter assays of 3ʹ UTR sequences of these cell cycle genes containing miR-33 target sites provided strong evidence for the direct interaction of miR-33 with these sequences.

The authors next addressed whether miR-33 affects cell proliferation and cell cycle progression. They showed that cell growth was inhibited when miR-33 was overexpressed, whereas cell proliferation was increased when miR-33 was inhibited. Transfection of miR-33 in synchronized cells resulted in cell cycle arrest in G~1~ phase. These effects on cell cycle and cell proliferation seem to be mediated by CDK6 and CCND1: their expression inversely correlated with that of miR-33 during the cell cycle, and they could be reduced by miR-33 transfection, even following mitogenic stimuli which usually induces their expression.

The role of miR-33 in cellular proliferation was further investigated in vivo by examining mouse liver regeneration following partial hepatectomy. Consistent with findings in cell culture, the authors observed an inverse correlation between the expression of miR-33 and those of CDK6 and CCND1, as well as with the proliferative status of liver cells. Anti-miR-33 treatment increased proliferative marker expression and accelerated liver regeneration, as determined by changes in liver-to-body mass ratio. Through the regulation of CCND1 and CDK6, miR-33 appears to be an important regulator of liver regeneration and may be a good target for liver disease treatment.

MiR-33 is currently being targeted as a therapeutic for atherosclerosis based on its inhibition of lipid metabolism-related genes, while this new work reveals its promise as a good target for liver regeneration. We must, though, take heed that therapies affecting cell cycle modulation may also cause undesirable consequences like cancer. In this important work, Cirera-Salinas et al. have filled in another piece of the puzzle linking lipid synthesis, cell cycle, SREBPs, and miR-33, with new findings hinting at a regulatory role for cholesterol in cell cycle progression.[@R9] Since we do not yet fully understand the impact of modulating miR-33, further research is needed to elucidate the reach of the SREBP/miR-33-mediated regulatory network and its therapeutic potential.
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